Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2020-09-18 AGM Information
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Book Closure
AGM Information Classification · 95% confidence The document text contains information about book closure dates, cut-off dates for voting eligibility, and remote e-voting commencement and end times specifically related to the 37th Annual General Meeting (AGM). These details are typical of materials shared to inform shareholders about the AGM process rather than the AGM report itself. The document length is short (533 characters), indicating it is likely an announcement or informational material related to the AGM rather than a full report or presentation. Therefore, the document fits the category of AGM Information (AGM-R).
2020-09-18 English
outcome of the Board Meeting held on 10th September, 2020
Regulatory Filings
2020-09-10 English
Outcome of Board Meeting
Regulatory Filings
2020-09-10 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Presentation" for the quarter ended June 30, 2020, and it is addressed to stock exchanges (BSE and NSE). It contains detailed business overview, market strategy, product pipeline, financial highlights, and growth outlook. The text explicitly states it is a presentation and includes forward-looking statements, disclaimers, and detailed segment information typical of investor presentations. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief earnings release or regulatory filing. The length (15,000 characters) and content depth support classification as an Investor Presentation rather than a short announcement or report publication notice. Therefore, the document fits best under the category Investor Presentation (IP).
2020-08-20 English
Investor Presentation for the quarter ended June 30, 2020
Regulatory Filings
2020-08-20 English
Declaration of interim dividend of Rs.1.25 ps. per equity share of Rs.2/- each for the financial year 2020-21. The date for taking a record of its shareholders eligible for the purpose ....
Regulatory Filings
2020-08-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.